BACKGROUND:Aromatase inhibitor (AI) therapy results in substantial survival benefits for patients with hormone receptor-positive breast cancer. The rates of poor adherence and discontinuation of AI therapy are high, primarily because of treatment-related toxicities like musculoskeletal pain. Although pain-related symptoms may worsen during AI therapy, the authors hypothesized that nonpersistence with AI therapy was associated with symptoms that were present before treatment initiation. METHODS:Postmenopausal women initiating AI therapy who were enrolled in a prospective clinical trial completed questionnaires at baseline to assess sleep, fatigue, mood, and pain. Reasons for treatment discontinuation during the first year of treatment were recorded. Associations between baseline patient-reported symptoms and treatment discontinuation because of toxicity were identified using logistic regression. RESULTS:Four hundred forty-nine patients were evaluable. The odds of treatment discontinuation were higher in patients who reported a greater number of symptoms before AI initiation. Baseline poor sleep quality was associated with early treatment discontinuation, with an odds ratio (OR) of 1.91 (95% confidence interval [CI], 1.26-2.89; P = .002). Baseline presence of tired feeling and forgetfulness had similar ORs for discontinuation (tired feeling: OR, 1.76; 95% CI, 1.15-2.67; P = .009; forgetfulness: OR, 1.66; 95% CI, 1.11-2.48; P = .015). An increasing total number of baseline symptoms was associated with an increased likelihood of treatment discontinuation, with an OR of 1.89 (95% CI, 1.20-2.96; P = .006) for 3 to 5 symptoms versus 0 to 2 symptoms. CONCLUSIONS: Symptom clusters in breast cancer survivors that are present before the initiation of adjuvant AI therapy may have a negative impact on a patient's persistence with therapy. Interventions to manage these symptoms may improve breast cancer outcomes and quality of life.
RCT Entities:
BACKGROUND:Aromatase inhibitor (AI) therapy results in substantial survival benefits for patients with hormone receptor-positive breast cancer. The rates of poor adherence and discontinuation of AI therapy are high, primarily because of treatment-related toxicities like musculoskeletal pain. Although pain-related symptoms may worsen during AI therapy, the authors hypothesized that nonpersistence with AI therapy was associated with symptoms that were present before treatment initiation. METHODS: Postmenopausal women initiating AI therapy who were enrolled in a prospective clinical trial completed questionnaires at baseline to assess sleep, fatigue, mood, and pain. Reasons for treatment discontinuation during the first year of treatment were recorded. Associations between baseline patient-reported symptoms and treatment discontinuation because of toxicity were identified using logistic regression. RESULTS: Four hundred forty-nine patients were evaluable. The odds of treatment discontinuation were higher in patients who reported a greater number of symptoms before AI initiation. Baseline poor sleep quality was associated with early treatment discontinuation, with an odds ratio (OR) of 1.91 (95% confidence interval [CI], 1.26-2.89; P = .002). Baseline presence of tired feeling and forgetfulness had similar ORs for discontinuation (tired feeling: OR, 1.76; 95% CI, 1.15-2.67; P = .009; forgetfulness: OR, 1.66; 95% CI, 1.11-2.48; P = .015). An increasing total number of baseline symptoms was associated with an increased likelihood of treatment discontinuation, with an OR of 1.89 (95% CI, 1.20-2.96; P = .006) for 3 to 5 symptoms versus 0 to 2 symptoms. CONCLUSIONS: Symptom clusters in breast cancer survivors that are present before the initiation of adjuvant AI therapy may have a negative impact on a patient's persistence with therapy. Interventions to manage these symptoms may improve breast cancer outcomes and quality of life.
Authors: Ann M Berger; Amy Pickar Abernethy; Ashley Atkinson; Andrea M Barsevick; William S Breitbart; David Cella; Bernadine Cimprich; Charles Cleeland; Mario A Eisenberger; Carmen P Escalante; Paul B Jacobsen; Phyllis Kaldor; Jennifer A Ligibel; Barbara A Murphy; Tracey O'Connor; William F Pirl; Eve Rodler; Hope S Rugo; Jay Thomas; Lynne I Wagner Journal: J Natl Compr Canc Netw Date: 2010-08 Impact factor: 11.908
Authors: Ivana Sestak; Jack Cuzick; Francisco Sapunar; Richard Eastell; John F Forbes; Angelo R Bianco; Aman U Buzdar Journal: Lancet Oncol Date: 2008-08-12 Impact factor: 41.316
Authors: Colin A Espie; Leanne Fleming; James Cassidy; Leslie Samuel; Lynne M Taylor; Craig A White; Neil J Douglas; Heather M Engleman; Heidi-Louise Kelly; James Paul Journal: J Clin Oncol Date: 2008-06-30 Impact factor: 44.544
Authors: Richard J Santen; Lawrence Demers; Susan Ohorodnik; J Settlage; Peter Langecker; D Blanchett; Paul E Goss; Shuping Wang Journal: Steroids Date: 2007-05-21 Impact factor: 2.668
Authors: Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: N L Henry; H-P Chan; J Dantzer; C P Goswami; L Li; T C Skaar; J M Rae; Z Desta; N Khouri; R Pinsky; S Oesterreich; C Zhou; L Hadjiiski; S Philips; J Robarge; A T Nguyen; A M Storniolo; D A Flockhart; D F Hayes; M A Helvie; V Stearns Journal: Br J Cancer Date: 2013-10-01 Impact factor: 7.640
Authors: Manali A Bhave; Kelly A Speth; Kelley M Kidwell; Angela Lyden; Cindy Alsamarraie; Susan L Murphy; N Lynn Henry Journal: Clin Breast Cancer Date: 2017-12-27 Impact factor: 3.225
Authors: Dawn L Hershman; Lawrence H Kushi; Grace Clarke Hillyer; Ellie Coromilas; Donna Buono; Lois Lamerato; Dana H Bovbjerg; Jeanne S Mandelblatt; Wei-Yann Tsai; Xiaobo Zhong; Judith S Jacobson; Jason D Wright; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2016-04-16 Impact factor: 4.872
Authors: Joan M Neuner; Nicole M Fergestrom; Purushottam W Laud; Ann B Nattinger; Kirsten M M Beyer; Kathryn E Flynn; Liliana E Pezzin Journal: Cancer Date: 2019-08-02 Impact factor: 6.860
Authors: Miryam Yusufov; Margo Nathan; Aleta Wiley; Julia Russell; Ann Partridge; Hadine Joffe Journal: Breast Cancer Res Treat Date: 2020-09-12 Impact factor: 4.872
Authors: Tracy D Vannorsdall; Ermiece Straub; Christina Saba; Mallory Blackwood; Jingyi Zhang; Keren Stearns; Karen Lisa Smith Journal: Support Care Cancer Date: 2020-10-21 Impact factor: 3.603